Company intelligence
ArteraAI
A leading precision medicine company, Artera develops AI-enabled tests to help personalize therapy for cancer patients.
Hospitals and Health Care
Los Altos, US
152 employees
4 public signals
About ArteraAI
Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer. Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.
Verified activity
Signals from ArteraAI
4 published signals
Research & Knowledge
ArteraAI VP of Medical Science Calvin Chao discussed how the ArteraAI Breast Test uses routine digital pathology slides and clinical information to provide risk stratification in approximately one hour.
Reported by ArteraAI
Presence & Recognition
ArteraAI is attending the Mid-Atlantic and South Central American Urological Association Annual Meetings in Roanoke and Tucson this September.
Reported by ArteraAI
Presence & Recognition
ArteraAI Medical Director Ben Fischer-Valuck, MD, MBA, MS, shares his perspective on the progress being made in prostate cancer and how precision medicine is helping clinicians better understand each patient's disease and make more informed treatment decisions.
Reported by ArteraAI
People
ArteraAI welcomed its newest team members to Artera.
Reported by ArteraAI